Sign In
2 Jun 2026 12:42
Hikma Pharmaceuticals PLC - LTIP and EIP Vesting
LONDON, 2 June 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (Nasdaq Dubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMRs") have received shares as a result of the vesting of their conditional share awards which were granted on 30 May 2023 under the 2023 Long-Term Incentive Plan ("LTIP") and 2014 Executive Incentive Plan ("EIP") Element C.
Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities
Said Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Said Darwazah | |
2 | Reason for the notification | ||
a) | Position/status | Chief Executive Officer | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | LTIP Award: 91,812 | ||
Nil | EIP Award, Element C: 19,761 | ||
d) | Aggregated information | Price(s): nil Volume(s): 111,573 | |
e) | Date of the transaction | 1 June 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Mazen Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Mazen Darwazah | |
2 | Reason for the notification | ||
a) | Position/status | Executive Vice Chairman and Deputy CEO, MENA | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | LTIP Award: 72,763 | ||
Nil | EIP Award, Element C: 20,650 | ||
d) | Aggregated information | Price(s): nil Volume(s): 93,413 | |
e) | Date of the transaction | 1 June 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Khalid Nabilsi
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Khalid Nabilsi | |
2 | Reason for the notification | ||
a) | Position/status | Deputy CEO, North America and Europe | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | LTIP Award: 51,650 | ||
Nil | EIP Award, Element C: 22,209 | ||
d) | Aggregated information | Price(s): nil Volume(s): 73,859 | |
e) | Date of the transaction | 1 June 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Bassam Kanaan
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Bassam Kanaan | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | LTIP Award: 52,640 | ||
Nil | EIP Award, Element C: 20,982 | ||
d) | Aggregated information | Price(s): nil Volume(s): 73,622 | |
e) | Date of the transaction | 1 June 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Hussein Arkhagha
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Hussein Arkhagha | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | LTIP Award: 28,631 | ||
Nil | EIP Award, Element C: 12,406 | ||
d) | Aggregated information | Price(s): nil Volume(s): 41,037 | |
e) | Date of the transaction | 1 June 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Susan Ringdal
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Susan Ringdal | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the LTIP and EIP. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | LTIP Award: 26,558 | ||
Nil | EIP Award, Element C: 11,664 | ||
d) | Aggregated information | Price(s): nil Volume(s): 38,222 | |
e) | Date of the transaction | 1 June 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | All shares sold following the vesting of conditional awards under the LTIP and EIP. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
£14.49 | LTIP Award: 26,558 | ||
£14.49 | EIP Award, Element C: 11,664 | ||
d) | Aggregated information | Price(s): £14.49 Volume(s): 38,222 Total(s): £553,748.83 | |
e) | Date of the transaction | 1 June 2026 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Helen MiddlemistGroup Company Secretary
+44 (0)20 7399 2760
Hikma Pharmaceuticals (HIK)
Follow the stocks
